Outcomes of SARS‐CoV‐2 infection among lung transplant recipients: A single center retrospective study

Alessio Casutt,Matthaios Papadimitriou‐Olivgeris,Foteini Ioakeim,John‐David Aubert,Oriol Manuel,Angela Koutsokera

DOI: https://doi.org/10.1111/tid.14007

2023-01-06

Transplant Infectious Disease

Abstract:Background Lung transplant recipients (LTRs) are at increased risk for coronavirus disease 2019 (COVID‐19)‐associated complications. Methods We aimed to describe the outcomes of polymerase chain reaction‐documented severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection in LTRs followed at our institution from March 2020 to July 2022. The primary outcome investigated was hospitalization or death from COVID‐19‐related symptoms within 28 days from diagnosis. Results Overall, 60 cases were included, of which 18 (30%) reached the primary outcome. Only one patient (2%) died. Anti‐spike monoclonal antibodies (mAbs) were administered as early treatment in 36 patients (casirivimab/imdevimab = 2, sotrovimab = 31, and tixagevimab/cilgavimab = 3). Multivariate analysis revealed that age >60 years (p = .003; odds ratio [OR] 9.41; confidence interval [CI] 2.52–41.05) was associated with a higher risk for the primary outcome, while administration of mAbs as early treatment (p = .030; OR 0.23; CI 0.06–0.87) was associated with a lower risk. No effect of vaccination and SARS‐CoV‐2 variant was observed. Forced expiratory volume in 1 s and forced vital capacity values did not decrease among 37 patients who had spirometry performed 1 month after COVID‐19. Conclusions We observed a relatively low morbidity and mortality of COVID‐19 in LTR. mAb administration was associated with a better outcome.

immunology,infectious diseases,transplantation